We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
In a recent study published in Archiv der Pharmazie, researchers explored the effectiveness of Ginkgo biloba L. folium extract (EGb) in the management of coronavirus disease 2019 (COVID-19) severity.
COVID-19 is associated with several inflammatory disorders as well as the manifestation of oxidative stress in severe cases. Therefore, the development of therapeutic approaches against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that target inflammation and oxidation can help alleviate COVID-19 complications.
Various studies have highlighted the broad‐spectrum antiviral activity of EGb and its impact on viral life cycle stages, such as viral binding, viral entry, expression of proteins, as well as assembly and release of proteins. This antiviral activity is mainly observed under the cytotoxic threshold. EGb is also known to have an inhibitory effect against influenza A and B viruses via disruption of the hemagglutinin (HA) to the host cells.
In the present study, the team noted that the transmissibility of the influenza A virus depends on the interactions between HA and neuraminidase (NA) with sialic acid present in the cell surface receptor. Ginkgetin, a natural biflavone isolated from GB, can effectively block the sialidase activity of the influenza virus, thus preventing viral adsorption on the host's cell surface. Furthermore, EGb has been found to have a substantial antiviral effect against the H3N2 influenza virus as well as the hepatitis B virus.
The antiviral effect of GB is reported to be due to the disruption of viral fusion and the protective effect induced by GB on the host cells by improving its stability and reducing its permeability. Furthermore, studies showed that isorhamnetin, a flavonoid present in EGb, can inhibit NA and HA found in the H1N1 virus. This flavonoid also reduced autophagy induced by a viral infection, production of reactive oxygen species, and the phosphorylation of mitogen-activated protein kinase.
EGb and its components have also displayed anti-inflammatory effects via the inhibition of proinflammatory cytokines and the activation of anti-inflammatory cytokines. Various studies have noted that biflavones present in EGb, such as ginkgetin, significantly reduce the abnormal expression of Akt and p38 pathways in the basal epithelial cells. Biflavones also suppressed the expression of messenger ribonucleic acid (mRNA) of respiratory tract mucin, which could lead to mucociliary clearance failure.
EGb was also found to reduce the inflammation of the airway in asthmatic patients by decreasing the infiltration of the inflammatory cells, such as lymphocytes and eosinophils. It also suppressed the activity of protein kinase alpha (PKC‐α) of lymphocytes, thus preventing the secretion of interleukin 5 (IL-5) in the epithelial cells of the respiratory system. Additionally, a diterpene trilactone of GB called ginkgolide B also reduced the inflammatory reactions incident in the airway of patients who have asthma by reducing the secretion of platelet-activating factor (PAF).
Evidence shows that the 3‐chymotrypsin‐like protease (3CLpro) enzyme plays a crucial role in SARS-CoV-2 replication and is considered an effective target against SARS-CoV-2. GA and a bioflavone called sciadopitysin present in EGb can sufficiently block 3CLpro. Moreover, glycosylated flavonoids found in EGb also display inhibitory effects on SARS-CoV-2 replication by suppressing the function of 3CLpro. The team also noted that a glycosylated derivative of kaempferol present in EGb has one of the highest binding energies to 3CLpro in SARS-CoV-2. Kaempferol inhibited the 3CLpro by exerting modularity effects on the extracellular as well as intercellular signaling pathways.
Furthermore, the papain‐like protease (PLpro) was also inhibited by quercetin, the primary component of the EGb flavonoids. This inhibition led to the suppression of SARS-CoV-2 replication through the inhibition of both PLpro and CLpro, which further resulted in the mitigation of coagulopathy, hyperinflammatory reactions as well as prothrombotic conditions. Moreover, the channel blocking activity of quercetin and kaempferol inhibited the SARS-CoV-2 envelope (E) protein, thus reducing viral activity and proliferation.
Various studies have highlighted the important role of lipoxygenase (LOX) and cyclooxygenase (COX) enzymes in worsening bronchial inflammatory reactions as well as the progression of acute lung injury (ALI) in patients experiencing severe COVID-19. Ginkgetin effectively inhibits leukotriene and prostaglandin pathways as a result of the reduction in phospholipase A2 enzyme activity. Altogether, this indicated that EGb showed great potential as a therapeutic approach against ALI.
Overall, the study findings showed that GB preparations could serve as effective potential candidates in the management of COVID-19 and its disease severity. The researchers believe that further clinical trial studies could verify the effectiveness of EGb against COVID-19 disease progression.
Ginkgo biloba in the management of the COVID-19 severity Al-kuraishy, H. M., Al-Gareeb, A. I., Kaushik, A., Kujawska, M., Batiha, G. E.-S., Arch. Pharm. doi: https://doi.org/10.1002/ardp.202200188 https://onlinelibrary.wiley.com/doi/10.1002/ardp.202200188
Posted in: Medical Science News | Medical Research News | Disease/Infection News
Tags: Anti-Inflammatory, Asthma, Autophagy, Cell, Clinical Trial, Coronavirus, Coronavirus Disease COVID-19, covid-19, Cytokines, Enzyme, Flavonoid, Ginkgo, H1N1, H3N2, Hepatitis, Hepatitis B, Hepatitis B Virus, Inflammation, Influenza, Interleukin, Interleukin 5, Kinase, Oxidative Stress, Oxygen, Phosphorylation, Platelet, Proliferation, Protein, Quercetin, Receptor, Respiratory, Ribonucleic Acid, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Stress, Syndrome, Virus
Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.
Please use one of the following formats to cite this article in your essay, paper or report:
Kunkalikar, Bhavana. (2022, June 13). The potential role of Ginkgo biloba L. folium extract in the management of COVID-19. News-Medical. Retrieved on June 18, 2022 from https://www.news-medical.net/news/20220613/The-potential-role-of-Ginkgo-biloba-L-folium-extract-in-the-management-of-COVID-19.aspx.
Kunkalikar, Bhavana. "The potential role of Ginkgo biloba L. folium extract in the management of COVID-19". News-Medical. 18 June 2022. <https://www.news-medical.net/news/20220613/The-potential-role-of-Ginkgo-biloba-L-folium-extract-in-the-management-of-COVID-19.aspx>.
Kunkalikar, Bhavana. "The potential role of Ginkgo biloba L. folium extract in the management of COVID-19". News-Medical. https://www.news-medical.net/news/20220613/The-potential-role-of-Ginkgo-biloba-L-folium-extract-in-the-management-of-COVID-19.aspx. (accessed June 18, 2022).
Kunkalikar, Bhavana. 2022. The potential role of Ginkgo biloba L. folium extract in the management of COVID-19. News-Medical, viewed 18 June 2022, https://www.news-medical.net/news/20220613/The-potential-role-of-Ginkgo-biloba-L-folium-extract-in-the-management-of-COVID-19.aspx.
News-Medical speaks to Henry Fingerhut, Senior Policy Analyst for Science & Innovation at the Tony Blair Institute for Global Change, about genomic surveillance and its associated opportunities and challenges.
Dr. Chenqu Suo and Dr. Cecilia Domínguez Conde
In this interview, News-Medical speaks to two researchers each discussing their respective studies that have contributed to the Human Cell Atlas; Dr. Chenqu Suo and Dr. Cecilia Domínguez Conde from the Wellcome Sanger Institute.
Irene Walsh and Professor Claire Smith
In this interview, News Medical speak to Irene Walsh, the director of Product, Design & Content, and 3D4Medical at Elsevier, and Professor Claire Smith, Head of Anatomy at Brighton and Sussex Medical School, about the real-world applications of the Complete Anatomy female model, the most advanced full female anatomy model in the world.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022